| Year |
Citation |
Score |
| 2023 |
Apollonio B, Spada F, Petrov N, Cozzetto D, Papazoglou D, Jarvis P, Kannambath S, Terranova-Barberio M, Amini RM, Enblad G, Graham CE, Benjamin R, Phillips EH, Ellis RJ, Nuamah R, ... ... Hagner PR, et al. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. The Journal of Clinical Investigation. PMID 37219943 DOI: 10.1172/JCI166070 |
0.357 |
|
| 2022 |
Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, et al. Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Ejhaem. 3: 139-153. PMID 35846221 DOI: 10.1002/jha2.375 |
0.323 |
|
| 2021 |
Wu W, Nelson G, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, Nirmal AJ, Liu H, Yang L, Duffy J, Powers F, Stevenson KE, Jones M, Ng SY, Wu G, ... ... Hagner PR, et al. Overcoming IMiD Resistance in T-cell Lymphomas Through Potent Degradation of ZFP91 and IKZF1. Blood. PMID 34936696 DOI: 10.1182/blood.2021014701 |
0.316 |
|
| 2020 |
Michot JM, Bouabdallah R, Vitolo U, Doorduijn JK, Salles G, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, ... ... Hagner PR, et al. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. The Lancet. Haematology. PMID 32758434 DOI: 10.1016/S2352-3026(20)30208-8 |
0.414 |
|
| 2020 |
Risueno A, Hagner PR, Towfic F, Fontanillo C, Djebbari A, Parker JS, Drew C, Nowakowski GS, Maurer MJ, Cerhan JR, Wei X, Ren Y, Lee CW, Couto S, Wang M, et al. Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. Blood. PMID 31977005 DOI: 10.1182/Blood.2019002414 |
0.425 |
|
| 2020 |
Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles GA, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin Garcia-Sancho A, ... ... Hagner PR, et al. Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier. Blood. PMID 31977002 DOI: 10.1182/Blood.2019002395 |
0.381 |
|
| 2020 |
Mehta-Shah N, Chavez JC, Abrisqueta P, Johnson N, Burgues JMB, Grande-Garcia C, Stewart D, Dunleavy K, Rodriguez G, Sancho J, Drew J, Wu C, Hagner PR, Delarue R, Martin A. Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL. Journal of Clinical Oncology. 38: 3501-3501. DOI: 10.1200/Jco.2020.38.15_Suppl.3501 |
0.366 |
|
| 2019 |
Chiu H, Trisal P, Bjorklund C, Carrancio S, Toraño EG, Guarinos C, Papazoglou D, Hagner PR, Beldi-Ferchiou A, Tarte K, Delfau-Larue MH, Morschhauser F, Ramsay AG, Gandhi AK. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. British Journal of Haematology. PMID 30767211 DOI: 10.1111/Bjh.15797 |
0.445 |
|
| 2019 |
Hagner PR, Chiu H, Chopra VS, Colombo MS, Patel N, Ortiz M, Loos RS, Towfic F, Waldman M, Gandhi AK. Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors Blood. 134: 306-306. DOI: 10.1182/Blood-2019-126681 |
0.354 |
|
| 2019 |
Hagner PR, Waldman M, Gray FD, Yura R, Hersey S, Chan H, Zhang M, Boss I, Gandhi AK. Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models Blood. 134: 1580-1580. DOI: 10.1182/Blood-2019-126115 |
0.426 |
|
| 2019 |
Wenzl K, Ortiz M, Stong N, Huang CC, Maurer MJ, Towfic F, Hagner PR, Nikbakht H, Stokes M, Lata S, Kamalakaran S, Mavrommatis K, Trotter M, King RL, Link BK, et al. Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma Blood. 134: 919-919. DOI: 10.1182/Blood-2019-123694 |
0.353 |
|
| 2019 |
Huang CC, Nakayama Y, Stokes M, Towfic F, Lee c, Ren Y, Marella M, Wang M, Hagner PR, Couto S, Newhall K, Gandhi AK. Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns Blood. 134: 2797-2797. DOI: 10.1182/Blood-2019-123691 |
0.37 |
|
| 2019 |
Ortiz M, Wenzl K, Stokes M, Huang CC, Maurer MJ, Towfic F, Hagner PR, Ratushny A, McConnell M, Danziger SA, Stong N, Lata S, Kamalakaran S, Mavrommatis K, Trotter M, et al. Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse Blood. 134: 923-923. DOI: 10.1182/Blood-2019-122756 |
0.343 |
|
| 2018 |
Rasco DW, Papadopoulos KP, Pourdehnad M, Gandhi AK, Hagner P, Li Y, Wei X, Chopra R, Hege K, DiMartino JF, Shih KC. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30201761 DOI: 10.1158/1078-0432.Ccr-18-1203 |
0.331 |
|
| 2018 |
Hagner PR, Towfic F, Schmitz F, Wang X, Weng AP, Pourdehnad M, Gandhi AK. Avadomide (CC-122) Alters T Cell Repertoire and Enhances Infiltration of Lymphocytes into Tumor Microenvironment in DLBCL Patients Blood. 132: 4211-4211. DOI: 10.1182/Blood-2018-99-114481 |
0.381 |
|
| 2018 |
Nakayama Y, Stokes ME, Waldman M, Hagner PR, Gandhi AK. Mechanism of Synergistic Effects on T Cell Activation By Avadomide (CC-122) and Nivolumab Blood. 132: 4133-4133. DOI: 10.1182/Blood-2018-99-114469 |
0.344 |
|
| 2018 |
Nastoupil LJ, Bijou F, Ribrag V, Chavez JC, Witzig TE, Andorsky DJ, Klein LM, Greenwald D, Santoro A, Corradini P, Flinn IW, Sangha R, Kenkre VP, Uttamsingh S, Hagner PR, et al. Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma Blood. 132: 1602-1602. DOI: 10.1182/Blood-2018-99-114409 |
0.326 |
|
| 2018 |
Ioannou N, Hagner PR, Towfic F, Gandhi AK, Stamatopoulos K, Patten PEM, Vardi A, Ramsay AG. Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling Blood. 132: 237-237. DOI: 10.1182/Blood-2018-99-111605 |
0.386 |
|
| 2017 |
Hagner PR, Chiu H, Ortiz M, Apollonio B, Wang M, Couto S, Waldman MF, Flynt E, Ramsay AG, Trotter M, Gandhi AK, Chopra R, Thakurta A. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. British Journal of Haematology. PMID 28771673 DOI: 10.1111/Bjh.14866 |
0.43 |
|
| 2017 |
Czuczman MS, Trněný M, Davies A, Rule SA, Linton K, Wagner-Johnston N, Gascoyne RD, Slack G, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, ... ... Hagner P, et al. A Phase 2/3 Multicenter, Randomized, Open-Label Study of Lenalidomide vs Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28381416 DOI: 10.1158/1078-0432.Ccr-16-2818 |
0.382 |
|
| 2017 |
Carpio C, Bouabdallah R, Ysebaert L, Sancho J, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco DW, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martín A, ... ... Hagner PR, et al. A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study Blood. 130: 4118-4118. DOI: 10.1182/Blood.V130.Suppl_1.4118.4118 |
0.426 |
|
| 2017 |
Ribrag V, Chavez JC, Vitolo U, Kaplan JB, Chandler JC, Santoro A, Corradini P, Flinn IW, Nastoupil L, Cassier PA, Sangha R, Kenkre VP, Advani RH, Isufi I, Witzig TE, ... ... Hagner PR, et al. CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Blood. 130: 1551-1551. DOI: 10.1182/Blood.V130.Suppl_1.1551.1551 |
0.41 |
|
| 2017 |
Chiu H, Hagner PR, Trisal P, Waldman M, Cavanaugh C, Gandhi AK. Combination of Lenalidomide and Rituximab (R2) Targets Immune Dysfunction in FL By Activating T and NK Cells Ex Vivo and Is Differentiated from Chemotherapy Blood. 130: 1531-1531. DOI: 10.1182/Blood.V130.Suppl_1.1531.1531 |
0.467 |
|
| 2016 |
Hagner PR, Chiu H, Waldman MF, Klippel A, Pourdehnad M, Gandhi AK, Thakurta A. CC-122 Exhibits Greater Preclinical Activity in Mantle Cell Lymphoma Than Lenalidomide through a Combination of Direct Cell-Autonomous and Increased Antibody Dependent Cell-Mediated Cytotoxicity Blood. 128: 4188-4188. DOI: 10.1182/Blood.V128.22.4188.4188 |
0.433 |
|
| 2016 |
Nowakowski GS, Laplant BR, Pederson L, Maurer MJ, Macon WR, King RL, Storhoff J, Dennis S, Gandhi AK, Thakurta A, Hagner PR, Rimsza L, Habermann TM, Cerhan JR, Witzig TE. Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma Blood. 128: 3035-3035. DOI: 10.1182/Blood.V128.22.3035.3035 |
0.396 |
|
| 2016 |
Ribrag V, Chavez JC, Kaplan JB, Vitolo U, Chandler JC, Santoro A, Corradini P, Cassier P, Flinn IW, Advani R, Sangha R, Isufi I, Kenkre VP, Hagner PR, Trowe T, et al. A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001 Blood. 128: 1849-1849. DOI: 10.1182/Blood.V128.22.1849.1849 |
0.359 |
|
| 2016 |
Bjorklund CC, Kang J, Lu L, Amatangelo M, Chiu H, Hagner P, Gandhi AK, Pourdehnad M, Klippel A, Thakurta A. CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models Blood. 128: 1592-1592. DOI: 10.1182/Blood.V128.22.1592.1592 |
0.43 |
|
| 2016 |
Simonelli M, Sepulveda J, Brandes A, Soria J, Edenfield J, Moreno V, Pérez-Larraya JG, Britten C, Cloughesy TF, Garcia MM, Balana C, Hagner P, Li Y, Wei X, Gandhi A, et al. ATIM-28. A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORS Neuro-Oncology. 18: vi24-vi24. DOI: 10.1093/Neuonc/Now212.093 |
0.313 |
|
| 2015 |
Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, Wang M, Ren Y, Couto S, Breider M, Ning Y, Gandhi AK, Daniel TO, Chopra R, Klippel A, et al. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer Journal. 5: e354. PMID 26430725 DOI: 10.1038/Bcj.2015.66 |
0.377 |
|
| 2015 |
Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, Raymon H, Narla RK, Barnes L, Khambatta G, Chiu H, et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. PMID 26002965 DOI: 10.1182/Blood-2015-02-628669 |
0.447 |
|
| 2015 |
Hagner P, Chiu H, Ortiz-Estevez M, Biyukov T, Brachman C, Trneny M, Arcaini L, Morschhauser F, Thyss A, Stilgenbauer S, Milpied N, Marks R, Musto P, Martinelli G, Heise C, et al. Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity Blood. 126: 821-821. DOI: 10.1182/Blood.V126.23.821.821 |
0.412 |
|
| 2015 |
Chiu H, Hagner P, Pourdehnad M, Daniel T, Chopra R, Klippel A, Klein C, Thakurta A, Gandhi AK. CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity Blood. 126: 4007-4007. DOI: 10.1182/Blood.V126.23.4007.4007 |
0.398 |
|
| 2015 |
Gandhi AK, Vincent R, Carpio C, Stoppa A, Gharibo MM, Damian S, Rasco DW, Ysebaert L, Cordoba R, Santoro A, Edenfield WJ, Pinto A, López-Martín JA, Sancho JM, Panizo C, ... ... Hagner P, et al. CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma Blood. 126: 2704-2704. DOI: 10.1182/Blood.V126.23.2704.2704 |
0.415 |
|
| 2015 |
Apollonio B, Fanous M, Benmebarek M, Devereux S, Hagner P, Pourdehnad M, Gandhi AK, Patten PE, Ramsay AG. CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse Blood. 126: 1738-1738. DOI: 10.1182/Blood.V126.23.1738.1738 |
0.425 |
|
| 2015 |
Carpio C, Ysebaert L, Cordoba R, Santoro A, López-Martín JA, Sancho JM, Panizo C, Gharibo MM, Rasco DW, Stoppa A, Damian S, Wei X, Hagner P, Hege K, Carrancio S, et al. CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma Blood. 126: 1494-1494. DOI: 10.1182/Blood.V126.23.1494.1494 |
0.401 |
|
| 2014 |
Bjorklund CC, Havens CG, Hagner PR, Gandhi AK, Wang M, Amatangelo MD, Lu L, Wang H, Breider M, Ren Y, Lopez-Girona A, Thakurta A, Klippel A, Chopra R. Degradation of Aiolos and Ikaros Followed By Downregulation of c-Myc and then IRF4 Leads to Programmed Cell Death in Myeloma Cells Sensitive to IMiDs® Immunomodulatory Compounds Blood. 124: 4700-4700. DOI: 10.1182/Blood.V124.21.4700.4700 |
0.405 |
|
| 2014 |
Ribrag V, Damien S, Gharibo M, Gironella M, Santoro A, Rasco DW, Edenfield W, Wei X, James A, Hagner P, Gandhi AK, Chopra R, DiMartino JF, Pourdehnad M, Stoppa A. CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma Blood. 124: 3500-3500. DOI: 10.1182/Blood.V124.21.3500.3500 |
0.465 |
|
| 2014 |
Hagner P, Wang M, Couto S, Breider M, Fontanillo C, Trotter M, Bjorklund CC, Havens CG, Raymon HK, Narla RK, Barnes L, Waldman M, Daniel T, Klippel A, Pourdehnad M, et al. CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways Blood. 124: 3035-3035. DOI: 10.1182/Blood.V124.21.3035.3035 |
0.474 |
|
| 2011 |
Dai B, Zhao XF, Mazan-Mamczarz K, Hagner P, Corl S, Bahassi el M, Lu S, Stambrook PJ, Shapiro P, Gartenhaus RB. Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nature Communications. 2: 402. PMID 21772273 DOI: 10.1038/Ncomms1404 |
0.4 |
|
| 2011 |
Mazan-Mamczarz K, Hagner PR, Zhang Y, Dai B, Lehrmann E, Becker KG, Keene JD, Gorospe M, Liu Z, Gartenhaus RB. ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes. Blood. 117: 2441-50. PMID 21209379 DOI: 10.1182/Blood-2010-09-310987 |
0.334 |
|
| 2011 |
Hagner PR, Mazan-Mamczarz K, Dai B, Balzer EM, Corl S, Martin SS, Zhao XF, Gartenhaus RB. Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5' terminal oligopyrimidine tract. Oncogene. 30: 1531-41. PMID 21102526 DOI: 10.1038/Onc.2010.533 |
0.358 |
|
| 2010 |
Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood. 115: 2127-35. PMID 20075156 DOI: 10.1182/Blood-2009-09-220020 |
0.338 |
|
| 2010 |
Hagner P, Mazan-Mamczarz K, Dai B, Gartenhaus RB. Abstract 3159: RPS6 controls the translation of 5’ terminal oligopyrimidine tract-containing mRNAs through a physical interaction that regulates the loading of these messages on the polysome Cancer Research. 70: 3159-3159. DOI: 10.1158/1538-7445.Am10-3159 |
0.353 |
|
| 2010 |
Mazan-Mamczarz K, Hagner P, Dai B, Liu Z, Gartenhaus RB. Abstract 1249: The role of ATM-dependent Chk2 activation on post-transcriptional gene regulation by RNA-binding protein, HuR: implications for lymphoma development in AT patients Cancer Research. 70: 1249-1249. DOI: 10.1158/1538-7445.Am10-1249 |
0.378 |
|
| 2009 |
Dai B, Zhao XF, Hagner P, Shapiro P, Mazan-Mamczarz K, Zhao S, Natkunam Y, Gartenhaus RB. Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma. Cancer Research. 69: 7835-43. PMID 19789340 DOI: 10.1158/0008-5472.Can-09-1606 |
0.421 |
|
| 2009 |
Hagner PR, Mazan-Mamczarz K, Dai B, Corl S, Zhao XF, Gartenhaus RB. Alcohol consumption and decreased risk of non-Hodgkin lymphoma: role of mTOR dysfunction. Blood. 113: 5526-35. PMID 19293424 DOI: 10.1182/Blood-2008-11-191783 |
0.33 |
|
| 2009 |
Mazan-Mamczarz K, Hagner P, Dai B, Corl S, Liu Z, Gartenhaus RB. Targeted suppression of MCT-1 attenuates the malignant phenotype through a translational mechanism. Leukemia Research. 33: 474-482. PMID 18824261 DOI: 10.1016/J.Leukres.2008.08.012 |
0.372 |
|
| 2008 |
Mazan-Mamczarz K, Hagner PR, Dai B, Wood WH, Zhang Y, Becker KG, Liu Z, Gartenhaus RB. Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach. Cancer Research. 68: 7730-5. PMID 18829526 DOI: 10.1158/0008-5472.Can-08-2393 |
0.359 |
|
| 2008 |
Mazan-Mamczarz K, Hagner PR, Corl S, Srikantan S, Wood WH, Becker KG, Gorospe M, Keene JD, Levenson AS, Gartenhaus RB. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene. 27: 6151-63. PMID 18641687 DOI: 10.1038/Onc.2008.215 |
0.363 |
|
| 2007 |
Nandi S, Reinert LS, Hachem A, Mazan-Mamczarz K, Hagner P, He H, Gartenhaus RB. Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage Oncogene. 26: 2283-2289. PMID 17016429 DOI: 10.1038/Sj.Onc.1210030 |
0.411 |
|
| 2007 |
Hagner P, Mazan-Mamczarz K, Corl S, Gartenhaus RB. Dominant-Negative Inhibition of MCT-1 Oncogene Attenuates a Malignant Phenotype through Translational Repression. Blood. 110: 4168-4168. DOI: 10.1182/Blood.V110.11.4168.4168 |
0.455 |
|
| Show low-probability matches. |